Compare Amgen, Inc. (AMGN) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? Amgen, Inc. trades at $356.6 (market cap $196.12B), while Vanguard Total International Stock Index Fund ETF trades at $84.03. The key difference: Amgen, Inc. pays a 2.77% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | VXUS | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $87.06 |
52-Week Low | $271.18 | $68.24 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VXUS trades at $85.34, up 0.52% on the day, with a neutral technical signal and bullish moving averages. The ETF offers broad international equity exposure across 8,738 stocks, providing diversification benefits. Recent news highlights its role in portfolio construction amid high U.S. valuations, with Vanguard surpassing iShares as the largest ETF provider in June 2026.
The outlook for VXUS is supported by its low-cost structure and global diversification, appealing for long-term investors seeking non-U.S. exposure. Risks include currency fluctuations and emerging market volatility. Analyst sentiment is neutral, with the ETF positioned as a core holding for balanced portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
